|Description||Medical Device and pharmaceuticals|
|Angel, 7/09 ||$2M|
|Venture Round, 11/09 ||$3M|
|Venture Round, 12/09 ||$563k|
|Venture Round, 1/11 |
Platinum Montaur Life Sciences
Echo Therapeutics (OTCBB: ECTE) is developing its Symphony tCGM System, a novel, non-invasive (needle-free), wireless, transdermal continuous transdermal glucose monitoring (tCGM) system for people with diabetes and for use in hospital critical care units, and a pipeline of specialty pharmaceutical products incorporating its proprietary AzoneTS transdermal drug reformulation technology.
Echo is leveraging its unique, long-term strategic development relationship with Cato Research, a global contract research and development organization (CRO) and an affiliate of Echo’s largest institutional investor, Cato BioVentures, to develop its pharmaceutical pipeline efficiently and cost-effectively.